title: The dead end of 5-fluorouracil double modulation and promise of continuous infusion schedules in the treatment of metastatic colorectal cancer.
authors.affiliation: Virchow-Kjinikum Humboldt-University, Berlin Robert-Rössle-Klinik, Germany. koehne@rrk-berlin.de
authors.forename: C H
authors.initials: CH
authors.lastname: Köhne
authors.forename: H
authors.initials: H
authors.lastname: Wilke
authors.forename: P
authors.initials: P
authors.lastname: Schöffski
authors.forename: H J
authors.initials: HJ
authors.lastname: Schmoll
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D001221:Aspartate Carbamoyltransferase / Q000037:antagonists & inhibitors; D001224:Aspartic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology; D017322:Clinical Trials, Phase II as Topic; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D003131:Combined Modality Therapy; D004176:Dipyridamole / Q000008:administration & dosage / Q000494:pharmacology; D004334:Drug Administration Schedule; D004357:Drug Synergism; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D007372:Interferons / Q000627:therapeutic use; D002955:Leucovorin / Q000008:administration & dosage / Q000494:pharmacology; D008113:Liver Neoplasms / Q000188:drug therapy / Q000201:enzymology / Q000556:secondary*; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage / Q000494:pharmacology; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors; D009711:Nucleotides / Q000378:metabolism; D010166:Palliative Care; D010746:Phosphonoacetic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology; D016032:Randomized Controlled Trials as Topic; D013940:Thymidylate Synthase / Q000037:antagonists & inhibitors
chemical_list: D000964:Antimetabolites, Antineoplastic; D004791:Enzyme Inhibitors; D007155:Immunologic Factors; D009363:Neoplasm Proteins; D009711:Nucleotides; D001224:Aspartic Acid; D004176:Dipyridamole; C013195:sparfosic acid; D007372:Interferons; D013940:Thymidylate Synthase; D001221:Aspartate Carbamoyltransferase; D010746:Phosphonoacetic Acid; D002955:Leucovorin; D005472:Fluorouracil; D008727:Methotrexate